IL2 and systemic lupus erythematosus: Another study discussed combined treatment of IL-2 (1 million IU/day, 3–5 days/4 weeks) and rapamycin (0.5 mg/day, once every other day) for refractory SLE patients (24 weeks’ treatment), reporting that the number of Treg cells at the 12th and 24th weeks was increased, and the SLEDAI score and the ratio of Th17/Treg cells were reduced (156).